Therapeutic Area: Oncology

A hotspot mutation in transcription factor IKZF3 drives B cell neoplasia via transcriptional dysregulation

Lazarian G., et al.
Cancer Cell
March 2021
Authors and Affiliates
Gregory Lazarian 1, Shanye Yin 2, Elisa Ten Hacken 2, Tomasz Sewastianik 3, Mohamed Uduman 4, Alba Font-Tello 5, Satyen H Gohil 6, Shuqiang Li 7, Ekaterina Kim 8, Heather Joyal 9, Leah Billington 9, Elizabeth Witten 9, Mei Zheng 10, Teddy Huang 11, Mariano Severgnini 12, Valerie Lefebvre 13, Laura Z Rassenti 14, Catherine Gutierrez 2, Katia Georgopoulos 15, Christopher J Ott 16, Lili Wang 17, Thomas J Kipps 18, Jan A Burger 8, Kenneth J Livak 19, Donna S Neuberg 20, Fanny Baran-Marszak 21, Florence Cymbalista 21, Ruben D Carrasco 22, Catherine J Wu 23; 1 Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; INSERM, U978, Université Paris 13, Bobigny, France; Laboratoire d'Hématologie, APHP Hôpital Avicenne, Bobigny, France. 2 Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA. 3 Harvard Medical School, Boston, MA, USA; Department of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Experimental Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland. 4 Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. 5 Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA. 6 Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA; Department of Academic Haematology, University College London, London, UK. 7 Broad Institute of MIT and Harvard, Cambridge, MA, USA; Translational Immunogenomics Lab, Dana-Farber Cancer Institute, Boston, MA, USA. 8 Department of Leukemia, the University of Texas MD Anderson Cancer Center, Houston, TX, USA. 9 Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. 10 Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA. 11 Broad Institute of MIT and Harvard, Cambridge, MA, USA. 12 Center for Immuno-Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA. 13 Laboratoire d'Hématologie, APHP Hôpital Avicenne, Bobigny, France. 14 Moores Cancer Center, University of California, San Diego, USA. 15 Cutaneous Biology Research Center, Massachusetts General Hospital, Charlestown, MA, USA. 16 Center for Cancer Research, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. 17 Department of Systems Biology, Beckman Research Institute, City of Hope National Comprehensive Cancer Center, Monrovia, CA, USA. 18 Division of Hematology-Oncology, Department of Medicine, Moores Cancer Center, University of California, San Diego, USA. 19 Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA. 20 Department of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA. 21 INSERM, U978, Université Paris 13, Bobigny, France; Laboratoire d'Hématologie, APHP Hôpital Avicenne, Bobigny, France. 22 Harvard Medical School, Boston, MA, USA; Department of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA. 23 Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA; Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA. Electronic address: cwu@partners.org.

Global analysis of shared T cell specificities in human non-small cell lung cancer enables HLA inference and antigen discovery

Chiou S., et al.
Immunity
March 2021
Authors and Affiliates
Shin-Heng Chiou 1, Diane Tseng 2, Alexandre Reuben 3, Vamsee Mallajosyula 1, Irene S Molina 1, Stephanie Conley 4, Julie Wilhelmy 5, Alana M McSween 1, Xinbo Yang 6, Daisuke Nishimiya 6, Rahul Sinha 4, Barzin Y Nabet 7, Chunlin Wang 1, Joseph B Shrager 8, Mark F Berry 9, Leah Backhus 8, Natalie S Lui 8, Heather A Wakelee 10, Joel W Neal 10, Sukhmani K Padda 2, Gerald J Berry 11, Alberto Delaidelli 12, Poul H Sorensen 12, Elena Sotillo 13, Patrick Tran 13, Jalen A Benson 9, Rebecca Richards 14, Louai Labanieh 15, Dorota D Klysz 13, David M Louis 1, Steven A Feldman 13, Maximilian Diehn 16, Irving L Weissman 4, Jianjun Zhang 17, Ignacio I Wistuba 18, P Andrew Futreal 19, John V Heymach 3, K Christopher Garcia 20, Crystal L Mackall 21, Mark M Davis 22; 1 Institute for Immunity, Transplantation and Infection, Stanford University, Stanford, CA 94305, USA. 2 Department of Medicine, Division of Oncology, Stanford University, Stanford, CA 94305, USA. 3 Department of Thoracic Head and Neck Medical Oncology, Division of Cancer Medicine, MD Anderson Cancer Center, Houston, TX 77030, USA. 4 Institute for Stem Cell Biology and Regenerative Medicine Institute, Stanford University, Stanford, CA 94305, USA. 5 Stanford Genome Technology Center, Stanford University, Stanford, CA 94305, USA. 6 Department of Molecular and Cellular Physiology and Structural Biology, Stanford University, Stanford, CA 94305, USA. 7 Department of Radiation Oncology, Stanford University, Stanford, CA 94305, USA. 8 Department of Cardiothoracic Surgery - Thoracic Surgery, Stanford University, Stanford, CA 94305, USA; Stanford Cancer Institute, Stanford, CA 94305, USA. 9 Department of Cardiothoracic Surgery - Thoracic Surgery, Stanford University, Stanford, CA 94305, USA. 10 Department of Medicine, Division of Oncology, Stanford University, Stanford, CA 94305, USA; Stanford Cancer Institute, Stanford, CA 94305, USA. 11 Department of Pathology, Stanford University, Stanford, CA 94305, USA. 12 Department of Molecular Oncology, British Columbia Cancer Research Centre, Vancouver, BC V5Z 1L3, Canada. 13 Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, CA 94305, USA. 14 Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, CA 94305, USA; Department of Pediatrics, Stanford University, Stanford, CA 94305, USA. 15 Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, CA 94305, USA; Department of Bioengineering, Stanford University, Stanford, CA 94305, USA. 16 Institute for Stem Cell Biology and Regenerative Medicine Institute, Stanford University, Stanford, CA 94305, USA; Department of Radiation Oncology, Stanford University, Stanford, CA 94305, USA; Stanford Cancer Institute, Stanford, CA 94305, USA. 17 Department of Thoracic Head and Neck Medical Oncology, Division of Cancer Medicine, MD Anderson Cancer Center, Houston, TX 77030, USA; Department of Genomic Medicine, Division of Cancer Medicine, MD Anderson Cancer Center, Houston, TX 77030, USA. 18 Department of Translational Molecular Pathology, Division of Pathology and Laboratory Medicine, MD Anderson Cancer Center, Houston, TX 77030, USA. 19 Department of Genomic Medicine, Division of Cancer Medicine, MD Anderson Cancer Center, Houston, TX 77030, USA. 20 Department of Molecular and Cellular Physiology and Structural Biology, Stanford University, Stanford, CA 94305, USA; Howard Hughes Medical Institute, Stanford University School of Medicine, Stanford, CA 94305, USA. 21 Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, CA 94305, USA; Department of Pediatrics, Stanford University, Stanford, CA 94305, USA; Department of Medicine, Stanford University, Stanford, CA 94305, USA. 22 Institute for Immunity, Transplantation and Infection, Stanford University, Stanford, CA 94305, USA; Howard Hughes Medical Institute, Stanford University School of Medicine, Stanford, CA 94305, USA; Department of Microbiology and Immunology, Stanford University, Stanford, CA 94305, USA. Electronic address: mmdavis@stanford.edu.

Molecular correlates of response to nivolumab at baseline and on treatment in patients with RCC

Ross-Macdonald P., et al.
Journal for ImmunoTherapy of Cancer
March 2021
Authors and Affiliates
Petra Ross-Macdonald 1, Alice M Walsh 1, Scott D Chasalow 1, Ron Ammar 1, Simon Papillon-Cavanagh 1, Peter M Szabo 1, Toni K Choueiri 2, Mario Sznol 3, Megan Wind-Rotolo 4; 1 Translational Medicine, Bristol Myers Squibb, Princeton, New Jersey, USA. 2 Department of Genitourinary Oncology, The Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts, USA. 3 Yale Cancer Center, Yale School of Medicine, New Haven, Connecticut, USA. 4 Translational Medicine, Bristol Myers Squibb, Princeton, New Jersey, USA megan.windrotolo@bms.com.

T-cell CX3CR1 expression as a dynamic blood-based biomarker of response to immune checkpoint inhibitors

Yamauchi T., et al.,
Nature Communications
March 2021
Authors and Affiliates
Takayoshi Yamauchi 1, Toshifumi Hoki 1,2, Takaaki Oba 1, Vaibhav Jain 1, Hongbin Chen 3,4, Kristopher Attwood 5, Sebastiano Battaglia 1,6, Saby George 3,4, Gurkamal Chatta 3, Igor Puzanov 3, Carl Morrison 7, Kunle Odunsi 1,8,9,10, Brahm H Segal 3,4,9, Grace K Dy 3, Marc S Ernstoff 3,4,11, Fumito Ito 12,13,14,15; 1 Center for Immunotherapy, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA. 2 Merck Sharp & Dohme, Tokyo, Japan. 3 Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA. 4 Department of Medicine, University at Buffalo Jacobs School of Medicine and Biomedical Sciences, The State University of New York, Buffalo, NY, USA. 5 Department of Biostatistics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA. 6 Department of Cancer Genetics and Genomics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA. 7 Department of Pathology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA. 8 Department of Gynecologic Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA. 9 Department of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA. 10 University of Chicago Comprehensive Cancer Center, Chicago, IL, USA. 11 Division of Cancer Treatment and Diagnosis, Developmental Therapeutics Program, National Cancer Institute, Bethesda, MD, USA. 12 Center for Immunotherapy, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA. fumito.ito@roswellpark.org. 13 Department of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA. fumito.ito@roswellpark.org. 14 Department of Surgical Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA. fumito.ito@roswellpark.org. 15 Department of Surgery, University at Buffalo Jacobs School of Medicine and Biomedical Sciences, The State University of New York, Buffalo, NY, USA. fumito.ito@roswellpark.org.

Tumor immune infiltration estimated from gene expression profiles predicts colorectal cancer relapse

Kamal Y, et al.,
OncoImmunology
March 2021
Authors and Affiliates
Yasmin Kamal 1, Dennis Dwan 1, Hannah J. Hoehn 2, Rebeca Sanz-Pamplona 3,4, M. Henar Alonso 3,4,5, Victor Moreno 3,4,5, Chao Cheng 6,7,8, Michael J. Schell 9, Youngchul Kim 9, Seth I. Felder 10, Hedy S. Rennert 11,12, Marilena Melas 13, 14, Charalampos Lazaris 13,15,16, Joseph D. Bonner 17, Erin M. Siegel 18, David Shibata 19, Gad Rennert 11,12, Stephen B. Gruber 7, H. Robert Frost 1, Christopher I. Amos 1,7,8, and Stephanie L. Schmit 2,10; 1 Department of Biomedical Data Sciences, Geisel School of Medicine at Dartmouth, Hanover, NH, USA 2 Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA 3 Oncology Data Analytics Program (ODAP), Catalan Institute of Oncology (ICO), ONCOBELL Program, Bellvitge Biomedical Research Institute (IDIBELL), Hospitalet de Llobregat, Barcelona, Spain 4 Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain 5 Department of Clinical Sciences, Faculty of Medicine, University of Barcelona, Barcelona, Spain 6 Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA 7 Department of Medicine, Baylor College of Medicine, Houston, TX, USA 8 Institute for Clinical and Translational Research, Baylor College of Medicine, Houston, TX, USA 9 Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center and Research Institute, Columbus, OH, USA 10 Department of Gastrointestinal Oncology, H. Lee Moffitt Cancer Center and Research Institute, Columbus, OH, USA 11 Department of Community Medicine & Epidemiology, Lady Davis Carmel Medical Center, Ruth & Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel 12 Steve and Cindy Rasmussen Institute for Genomic Medicine, Lady Davis Carmel Medical Center and Technion Faculty of Medicine, Clalit National Cancer Control Center, Haifa, Israel 13 Department of Medical Oncology and Therapeutics Research, Center for Precision Medicine, City of Hope National Medical Center, Duarte, CA, USA 14 Nationwide Children’s Hospital, Columbus, OH, USA 15 Whitehead Institute for Biomedical Research, Cambridge, MA, USA 16 Klarman Cell Observatory, Broad Institute of MIT and Harvard, Cambridge, MA, USA 17 Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, CA, USA 18 Cancer Epidemiology Program, H. Lee Moffitt Cancer Center and Research Institute, Columbus, OH, USA 19 Department of Surgery, University of Tennessee Health Science Center, Memphis, TN, USA

CD52/GPI-negative T-cells are enriched for alloreactive specificity and predict acute GvHD after stem cell transplantation.

Kinsella FA., et al.
March 2021
Authors and Affiliates
Francesca A. Kinsella 1,2, Charlotte. F. Inman 1, Wayne Croft 1, Jianmin Zuo 1, Hayden Pearce 1, Sara Barbieri 2, Charles Craddock 2, Ram Malladi 2, Paul Moss 1,2; 1 Institute of Immunology and Immunotherapy, College of Medical and Dental Studies, University of Birmingham and Birmingham Health Partners, Birmingham, UK 2 Centre for Clinical Haematology, Queen Elizabeth NHS Foundation Trust and Birmingham Health Partners, Birmingham, UK

VJ Segment Usage of TCR-Beta Repertoire in Monozygotic Cystic Fibrosis Twins

Fischer S., et al.
Frontiers in Immunology
March 2021
immuneAccess
Authors and Affiliates
Sebastian Fischer 1, Frauke Stanke 1,2 and Burkhard Tümmler 1,2; 1 Clinic for Pediatric Pneumology, Allergology and Neonatology, Hannover Medical School, Hannover, Germany 2 Biomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATH), German Center for Lung Research, Hannover Medical School, Hannover, Germany

Systemic Inflammation and Tumour-Infiltrating T-Cell Receptor Repertoire Diversity Are Predictive of Clinical Outcome in High-Grade B-Cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements

Olschewski V., et al.
Cancers
March 2021
immuneAccess
Authors and Affiliates
Vito Olschewski 1,†, Hanno M. Witte 1,2,3,† , Veronica Bernard 4,†, Konrad Steinestel 3 , Wolfgang Peter 5,6, Hartmut Merz 4, Johannes Rieken 1, Harald Biersack 1, Nikolas von Bubnoff 1 , Alfred C. Feller 4 and Niklas Gebauer 1,*; 1 Department of Haematology and Oncology, University Hospital of Schleswig-Holstein, Campus Lübeck, Ratzeburger Allee 160, 23538 Lübeck, Germany 2 Department of Hematology and Oncology, Federal Armed Forces Hospital Ulm, Oberer Eselsberg 40, 89081 Ulm, Germany 3 Institute of Pathology and Molecular Pathology, Federal Armed Forces Hospital of Ulm, Oberer Eselsberg 40, 89081 Ulm, Germany 4 Hämatopathologie Lübeck, Reference Center for Lymph Node Pathology and Hematopathology, 23562 Lübeck, Germany 5 HLA Typing Laboratory of the Stefan-Morsch-Foundation, 55765 Birkenfeld, Germany 6 Institute for Transfusion Medicine, University Hospital of Cologne, Kerpenerstr 62, 50937 Köln, Germany * Author to whom correspondence should be addressed. † These authors contributed equally to this manuscript.

Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial

Cascone T., et al.
February 2021
immuneAccess
Authors and Affiliates
Tina Cascone 1, William N William Jr 2,3, Annikka Weissferdt 4,5, Cheuk H Leung 6, Heather Y Lin 6, Apar Pataer 5, Myrna C B Godoy 7, Brett W Carter 7, Lorenzo Federico 8, Alexandre Reuben 2, Md Abdul Wadud Khan 9, Hitoshi Dejima 10,11, Alejandro Francisco-Cruz 10, Edwin R Parra 10, Luisa M Solis 10, Junya Fujimoto 10, Hai T Tran 2, Neda Kalhor 4, Frank V Fossella 2, Frank E Mott 2, Anne S Tsao 2, George Blumenschein Jr 2, Xiuning Le 2, Jianjun Zhang 2, Ferdinandos Skoulidis 2, Jonathan M Kurie 2, Mehmet Altan 2, Charles Lu 2, Bonnie S Glisson 2, Lauren Averett Byers 2, Yasir Y Elamin 2, Reza J Mehran 5, David C Rice 5, Garrett L Walsh 5, Wayne L Hofstetter 5, Jack A Roth 5, Mara B Antonoff 5, Humam Kadara 10, Cara Haymaker 10, Chantale Bernatchez 8,10, Nadim J Ajami 12, Robert R Jenq 12,13,14, Padmanee Sharma 15,16, James P Allison 16, Andrew Futreal 12, Jennifer A Wargo 9, Ignacio I Wistuba 2,10, Stephen G Swisher 5, J Jack Lee 6, Don L Gibbons 2, Ara A Vaporciyan 5, John V Heymach #,2,17, Boris Sepesi #,5; 1 Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. tcascone@mdanderson.org. 2 Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. 3 Oncology Center, Hospital BP, a Beneficencia Portuguesa de São Paulo, São Paulo, Brazil. 4 Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. 5 Thoracic and Cardiovascular Surgery, University of Texas MD Anderson Cancer Center, Houston, TX, USA. 6 Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX, USA. 7 Thoracic Imaging, University of Texas MD Anderson Cancer Center, Houston, TX, USA. 8 Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. 9 Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. 10 Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. 11 Teikyo University School of Medicine, Itabashi, Tokyo, Japan. 12 Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA. 13 Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX, USA. 14 CPRIT Scholar in Cancer Research, Houston, TX, USA. 15 Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. 16 Immunology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. 17 Cancer Biology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. # Contributed equally.

Common clonal origin of conventional T cells and induced regulatory T cells in breast cancer patients

Xydia M., et al.
Nature Communications
February 2021
Authors and Affiliates
Maria Xydia 1,2, Raheleh Rahbari 3, Eliana Ruggiero 4, Iain Macaulay 3,5, Maxime Tarabichi 3,6, Robert Lohmayer 7,8, Stefan Wilkening 4, Tillmann Michels 7, Daniel Brown 9,10, Sebastiaan Vanuytven 6,9, Svetlana Mastitskaya 11,12, Sean Laidlaw 3, Niels Grabe 11,13, Maria Pritsch 14, Raffaele Fronza 4, Klaus Hexel 15, Steffen Schmitt 15, Michael Müller-Steinhardt 16, Niels Halama 11,13, Christoph Domschke 17, Manfred Schmidt 4, Christof von Kalle 4,18, Florian Schütz 17, Thierry Voet 3,9, Philipp Beckhove 19,20; 1 RCI Regensburg Centre for Interventional Immunology, University and Department of Hematology/Oncology, University Medical Centre of Regensburg, Regensburg, Germany. Maria.Xydia@ukr.de. 2 Translational Immunology Department, German Cancer Research Centre, Heidelberg, Germany. Maria.Xydia@ukr.de. 3 The Cancer, Ageing and Somatic Mutation Program, Wellcome Sanger Institute, Hinxton, UK. 4 Translational Oncology Department, National Centre for Tumor Diseases and German Cancer Research Centre, Heidelberg, Germany. 5 Technical Development, Earlham Institute, Norwich, UK. 6 The Francis Crick Institute, London, UK. 7 RCI Regensburg Centre for Interventional Immunology, University and Department of Hematology/Oncology, University Medical Centre of Regensburg, Regensburg, Germany. 8 Institute for Theoretical Physics, University of Regensburg, Regensburg, Germany. 9 Department of Human Genetics, University of Leuven, KU Leuven, Leuven, Belgium. 10 The Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia. 11 Medical Oncology Department, National Centre for Tumor Diseases, Heidelberg, Germany. 12 Centre for Cardiovascular and Metabolic Neuroscience, Department of Neuroscience, Physiology and Pharmacology, University College London, London, UK. 13 Hamamatsu Tissue Imaging and Analysis Centre, BIOQUANT, University of Heidelberg, Heidelberg, Germany. 14 Translational Immunology Department, German Cancer Research Centre, Heidelberg, Germany. 15 Flow Cytometry Core Facility, German Cancer Research Centre, Heidelberg, Germany. 16 German Red Cross (DRK Blood Donation Service in Baden-Württemberg-Hessen) and Institute for Transfusion Medicine and Immunology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany. 17 Department of Gynecology and Obstetrics, University Hospital of Heidelberg, Heidelberg, Germany. 18 Clinical Study Centre, Charité/BIH, Berlin, Germany. 19 RCI Regensburg Centre for Interventional Immunology, University and Department of Hematology/Oncology, University Medical Centre of Regensburg, Regensburg, Germany. beckhove@rcii.de. 20 Translational Immunology Department, German Cancer Research Centre, Heidelberg, Germany. beckhove@rcii.de.